poisar

Stocks · News reference

Truist Securities Maintains Hold on Apogee Therapeutics, Raises Price Target to $135

Benzinga Newsdesk

Truist Securities analyst Danielle Brill maintains Apogee Therapeutics (NASDAQ:APGE) with a Hold and raises the price target from $81 to $135.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

APGE
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — Apogee Therapeutics, Inc. (APGE)

    Filed: 2026-09-03 AccNo: 0001140361-26-035537 Size: 348 KB Item 1.02: Termination of a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits

    APGE